Scienza e Tecnologia
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
Dr. Matt Coffey, President & Chief Executive Officer of Oncolytics Biotech Inc.
Wednesday, May 19, 2021
5:25 pm Eastern Daylight Time
Please click here
The Company will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please contact your RBC representative or email tim@lifesciadvisors.com.
A live webcast of the fireside chat will also be available on the Investor Relations page of Oncolytics' website (LINK) and will be archived for two weeks.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies of pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
Director of IR & Communication
+1-858-886-7813
jpatton@oncolytics.ca
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/1064079/Oncolytics_Logo.jpg